Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis

Podobne zapisy

• Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
  od: Suzuki, Yasuo, i wsp.
  Wydane: (2017)
• Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
  od: Suzuki, Yasuo, i wsp.
  Wydane: (2017)
• Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy
  od: Motoya, Satoshi, i wsp.
  Wydane: (2018)
• First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
  od: Kobayashi, Taku, i wsp.
  Wydane: (2015)
• Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis
  od: Suzuki, Yasuo, i wsp.
  Wydane: (2019)